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Introduction: While non-invasive ventilation aimed at avoiding intubation has become the modality of choice to
treat mild to moderate acute respiratory acidosis, many severely acidotic patients (pH <7.20) still need intubation.
Extracorporeal veno-venous CO2 removal (ECCO2R) could prove to be an alternative. The present animal study
tested in a systematic fashion technical requirements for successful ECCO2R in terms of cannula size, blood and
sweep gas flow.
Methods: ECCO2R with a 0.98 m
2 surface oxygenator was performed in six acidotic (pH <7.20) pigs using either a 14.5 French
(Fr) or a 19Fr catheter, with sweep gas flow rates of 8 and 16 L/minute, respectively. During each experiment the blood flow
was incrementally increased to a maximum of 400 mL/minute (14.5Fr catheter) and 1000 mL/minute (19Fr catheter).
Results: Amelioration of severe respiratory acidosis was only feasible when blood flow rates of 750 to 1000 mL/minute
(19Fr catheter) were used. Maximal CO2-elimination was 146.1 ± 22.6 mL/minute, while pH increased from 7.13 ±
0.08 to 7.41 ± 0.07 (blood flow of 1000 mL/minute; sweep gas flow 16 L/minute). Accordingly, a sweep gas flow of
8 L/minute resulted in a maximal CO2-elimination rate of 138.0 ± 16.9 mL/minute. The 14.5Fr catheter allowed a
maximum CO2 elimination rate of 77.9 mL/minute, which did not result in the normalization of pH.
Conclusions: Veno-venous ECCO2R may serve as a treatment option for severe respiratory acidosis. In this porcine
model, ECCO2R was most effective when using blood flow rates ranging between 750 and 1000 mL/minute, while an
increase in sweep gas flow from 8 to 16 L/minute had less impact on ECCO2R in this setting.Introduction
Non-invasive ventilation (NIV) has become the modality
of choice to treat mild to moderate respiratory acidosis
(pH ≥7.20) due to chronic obstructive pulmonary disease
(COPD) exacerbation, since it has been shown to avoid in-
tubation and intubation-related complications, resulting in
reduced ICU-mortality [1]. However, real-life observations
have revealed high rates of both intubation and mortality in
patients with COPD exacerbation and severe acute hyper-
capnic respiratory failure [2-4]. This is related to severe* Correspondence: karagiannidisc@kliniken-koeln.de
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article, unless otherwise stated.respiratory acidosis, well-established contraindications of
NIV, lack of staff training and the presence of co-morbidities
hindering the successful application of NIV [5,6].
This has led to the attempt of extracorporeal carbon
dioxide (CO2) removal (ECCO2R) in patients presenting
with acute hypercapnic respiratory failure. ECCO2R sys-
tems have been successfully used to reduce invasiveness
of mechanical ventilation and, therefore, ventilator-induced
lung injury in acute respiratory distress syndrome (ARDS)
patients [7-12]. Recently, ECCO2R by means of a pump-
less, arterio-venous extracorporeal lung-assist has been
shown to preclude the need for intubation and invasive
mechanical ventilation in a case–control study in COPD
patients with acute-on-chronic respiratory failure [13]. In
addition, previous research has demonstrated that this
technique is capable of eliminating approximately 50% of
the calculated CO2 production, with rapid normalizationentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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driven by the arterio-venous pressure gradient; thus, can-
nulation of arterial vessels (most commonly the femoral ar-
tery), coupled with cannulation of the corresponding vein
on the contralateral limb, is necessary for driving the sys-
tem [13-15]. Based on these preconditions, there are clearly
defined contraindications and several complications directly
related to arterial cannulation, such as bleeding, hematoma
or aneurysm at the insertion site, and ischemia and/or
compartment syndrome of the lower limb [15,16].
Interestingly, a recent study reported the successful ap-
plication of a pump-driven veno-venous system using a
15.5 French (Fr) dual-lumen catheter with a mean blood
flow of 431 ml/minute [17]. Even though this was a pilot
study testing the feasibility of this new approach, the study
showed the potential of these veno-venous systems to im-
prove respiratory acidosis without requiring arterial can-
nulation. However, patients only had moderate respiratory
acidosis, and it remains unclear how these results translate
to more severe respiratory acidosis. Accordingly, clinical
experience suggests that substantially higher flow rates are
needed to correct severe respiratory acidosis (pH <7.2)
[18]. In this regard, the physiological relationships be-
tween cannula size, blood flow, sweep gas flow and gas
transfer capacity, respectively, are still largely unknown.
For this reason, more physiological data on these issues
are needed before the promising technique of miniatur-
ized veno-venous ECCO2R can be tested in a broader clin-
ical setting. Therefore, we set up an animal study that
aimed to elucidate the relationships between cannula size,
blood flow and sweep gas flow, respectively, in pigs with
experimentally-induced severe respiratory acidosis that
mimicked severe acute hypercapnic respiratory failure
with pH values between 7.0 and 7.2.
Material and methods
Extracorporeal CO2 removal techniques
For ECCO2R a pump assisted lung protection (PALP)
System® (Maquet Cardiopulmonary Care, Rastatt, Germany)
based on the Cardiohelp® platform was used. The oxygen-
ator has an area of 0.98 m2 with a poly methylpentene
membrane lacking heat exchange fibers. The priming vol-
ume of the whole system is 247 ml. The PALP system® was
primed with normal saline solution. Heparin (1,000 IE) was
added to the running system.
For venous access, a 14.5Fr hemodialysis catheter (Fre-
senius Medical Care, Bad Homburg Germany) was used
during Experiments 1 and 2, while a 19Fr Bicaval Avalon
ELITE Dual Lumen Cannula® (Maquet Cardiopulmonary
Care, Rastatt, Germany) was implanted for Experiments
3, 4 and 5. Pigs were anticoagulated with heparin during
extracorporeal treatment. For all experiments, the sweep
gas flow was applied with 100% oxygen by a Flow-i
Anesthesia Delivery System (Maquet Critical Care, Solna,Sweden); in a subset of animals the sweep gas flow was
provided with room air.
Animal model
The study was approved by the Animal Research Com-
mittee of Uppsala University in Sweden (ethical approval
number: C265/12). Pigs (body weight = 39.8 ± 2.9 kg)
were anesthetized with IV ketamine 25 to 50 mg/kg/
hour, midazolam 90 to 180 μg/kg/hour, fentanyl 3 to
6 μg/kg/hour and rocuronium 2.5 to 5.0 mg/kg/hour.
The trachea was intubated with a cuffed endotracheal
tube (inner diameter, 7 mm). The pigs were ventilated
with a Servo-i ventilator (Maquet Critical Care, Solna,
Sweden). Body temperature was kept at 37°C throughout
the whole study period by the use of a warm blanket.
Arterial blood was taken from the left carotid artery.
The estimated CO2 production is about 7 ml/kg/minute
in pigs [19], that is, a CO2 production of approximately
280 ml/minute, which is comparable to an adult human.
Study design
ECCO2R was performed in six pigs following intubation,
mechanical ventilation and induction of respiratory acid-
osis by increased dead space ventilation. In detail, ana-
tomical dead space was increased by adding a further
tube between the endotracheal tube and the ‘Y’ piece of
the ventilator circuit. The length of the additional tube
was titrated until respiratory acidosis was induced with a
pH value of 7.0 to 7.1. Pigs were ventilated in a volume
controlled mode with a tidal volume of 360 ml, a posi-
tive end expiratory pressure (PEEP) of 6 cm H2O and a
breathing frequency of 15/minute. Dead space fractions
and CO2 elimination were measured with a NICO moni-
tor (Philips, Wallingford, CT, USA), where airway flow
and CO2 signals were monitored by mainstream sensors
placed between the endotracheal tube and the ‘Y’ piece
of the ventilator circuit. Dead space was computed as
PCO2et–PeCO2/PCO2et, where PCO2et represents the
end-tidal partial pressure of CO2 and PeCO2 the mixed
expired CO2. Dead space fraction was measured in the
first pig by the Bohr equation, with a resulting fraction
of 0.85. This dead space fraction was subsequently main-
tained for the entire duration of the experimental period.
Five experiments were performed in each pig in a stan-
dardized fashion. First, ECCO2R was performed via a 14.5Fr
hemodialysis catheter inserted into the right jugular vein
(experiments 1 and 2). Subsequently, ECCO2R was per-
formed via the 19Fr catheter following re-catheterization of
the same right jugular vein (experiments 3, 4, and 5).
Correct placement of the 19Fr cannula was confirmed
by echocardiography. Equal conditions were used across
all experiments (lasting at least 60 minutes), with each
experiment starting at the pre-determined acidotic
conditions.
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creased in a stepwise fashion, while sweep gas flow was
maintained (Table 1). Each step lasted 15 minutes in
order to achieve equilibrium conditions, with all mea-
surements taken at the end of this 15-minute period.
During experiment 5, sweep gas flow was changed by
increasing flow in a stepwise approach (Table 1), while
blood flow was maintained at a rate of 1,000 ml/min.
Each step lasted 15 minutes in order to achieve equilib-
rium conditions.
CO2 and blood gas measurement
CO2 was measured in the mainstream of the exhaust/
sweep-gas outlet of the oxygenator by the Vaisala Carbo-
cap GM 70 (Vaisala, Bonn, Germany). A water trap was
integrated into the circuit before CO2 measurement. CO2
removal was calculated by multiplying the sweep gas flow
with CO2 in Vol% in the exhaust/sweep-gas outlet. CO2
was measured with 0.04 Vol% in fresh air. Blood gas
analysis was performed with an ABL 800, Radiometer,
(Copenhagen, Denmark).
Statistics
For statistical analysis, GraphPad Prism 5 for Macintosh
computer (La Jolla, CA USA) was used. Data were tested
for normality using the Kolmogorov-Smirnov test with a
cut-off P value of <0.05. Normally-distributed data are
expressed as mean and standard deviation.
Results
ECCO2R was most effective with the 19Fr catheter at
higher blood flow levels (experiments 3 and 4; Figure 1),
with no clear difference between different sweep gas flow
(8 versus 16 L/minute) conditions. In contrast, ECCO2R
was less efficient with the 14.5Fr catheter (experiments 1
and 2; Figure 1). As a consequence, partial pressure of
CO2 in arterial blood (PaCO2) progressively decreased
with increasing blood flow when the 19Fr catheter, but
not the 14.5Fr catheter, was used (Figure 2). Similarly, pH
values progressively increased in proportion with bloodTable 1 Experimental set-up (experiments 1 to 5)
Parameter Experiment Experiment
1 2
Catheter size (French) 14.5 14.5
Sweep gas flow (L/min) 8 16
Blood flow (ml/min) 0 0
200 200
400 400flow with the 19Fr catheter, but not the 14.5Fr catheter
(Figure 3). Of note, non-acidotic blood gas values were
only achieved with 19Fr catheters at blood flow rates ran-
ging from 750 to 1,000 ml/minute. Detailed data on CO2
elimination and related blood gas values relative to differ-
ent blood flow levels at a sweep gas flow of 16 L/minute
are provided in Tables 2 and 3 and Additional file 1, re-
spectively. The absolute values of CO2 elimination were
normalized to the partial pressure of CO2 in venous blood
(PvCO2) and a partial pressure of CO2 (PCO2) value of
45 mmHg according to Wearden et al. [20] and are pro-
vided in Figure 4.
Corresponding data for different sweep gas flows were
comparable, where a higher sweep gas flow of 16 L/minute
resulted in only a slightly more effective ECCO2R com-
pared to a lower sweep gas flow of 8 L/minute (Tables 2
and 3 and Additional file 1). However, a sweep gas flow
below 6 L/minute resulted in less effective ECCO2R when
large (19Fr) catheters were used at high blood flow levels
(1,000 ml/minute) (Figure 5). The extracorporeal system
was more effective with higher PvCO2 and lower blood
flow levels and a longer oxygenator contact time, as dem-
onstrated by a lower PCO2 post-oxygenator (Figure 6).
In three pigs, the sweep gas flow was switched from
100% oxygen to room air at the end of experiment 5,
with blood flow rates of 1,000 ml/minute. This resulted
in a further increase in CO2 removal (150 ± 26.6 versus
159.8 ± 22.6 ml/minute).Discussion
The present porcine study indicates that pump-driven
veno-venous ECCO2R can normalize pH values and re-
duce PaCO2 in severe, life-threatening respiratory acid-
osis under constant ventilatory support. In addition, the
present study suggests that a blood flow of 750 to
1,000 ml/minute is needed to achieve these results, since
pH values remained acidotic at lower blood flow rates.
In particular, the severe respiratory acidosis in the
model used in this study could not be sufficiently cor-
rected either by ECCO2R at a blood flow of 200 toExperiment Experiment Experiment
3 4 5
19 19 19






Figure 1 Elimination of carbon dioxide (CO2) depending on blood flow. A) 14.5Fr catheter; 8 L/minute sweep gas flow. B) 14.5Fr catheter;
16 L/minute sweep gas flow. C) 19Fr catheter; 8 L/minute sweep gas flow. D) 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.
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flow rates of 500 ml/minute using the 19Fr cannula. In
contrast, severe respiratory acidosis was normalized by
veno-venous ECCO2R using the 19Fr catheter and a
blood flow rate of 1,000 ml/minute, even though a blood
flow of 750 ml/minute was sufficient in 50% of the ani-
mals. This finding contrasts with a recent study in hu-
man patients, where the application of a pump-driven
veno-venous system using a 15.5Fr dual-lumen catheter
was successful with a mean blood flow of 431 ml/minute
[17]. Importantly, however, the mean pH in that study
was around 7.25, thus considerably higher compared to
the pH in the present study. Thus, based on the current
findings, it remains questionable whether more acidotic
pH values could also be successfully corrected by lower
blood flow rates, although the 15.5Fr catheter has a
more favorable design compared to the 14.5Fr Shaldon
catheter. Therefore, using low-diameter catheters and low
blood flow rates, pump-driven veno-venous ECCO2R may
be primarily feasible in patients with mild to moderate re-
spiratory acidosis. This may be aimed at reducing aggres-
siveness of invasive ventilation as originally, and also
recently, described in patients with ARDS [7,9,12,21,22].
Interestingly, the ECCO2R capacity of the system used
in the present study was in line with previous findingsthat were also derived from an animal study, where a
removal-capacity up to 150 ml CO2/minute could be
achieved with a blood flow of 1,000 ml/minute and an
18Fr catheter [23]. In accordance with the present trial,
lower blood flow rates resulted in less efficient ECCO2R.
In clear contrast, however, the mentioned trial provided
evidence that ventilation parameters could be reduced
following ECCO2R, but again, animals were not as se-
verely acidotic as those in the present study. Therefore,
the current study provides the first evidence that even
severe acidosis can be successfully managed by ECCO2R
and, in agreement with our clinical experience, this was
only feasible with catheters that allowed blood flow rates
of 750 to 1,000 ml/minute.
Since intensive care specialists are familiar with 14.5Fr
hemodialysis catheters, it would be reasonable to test
whether these catheters also qualify for ECCO2R. How-
ever, the maximal blood flow through these catheters is
physiologically restricted to approximately 400 ml/minute.
Furthermore, catheters specifically designed for ECCO2R
aim to avoid recirculation [24,25]; this is particularly evi-
dent if the PCO2 of the venous blood, which is directed
towards the oxygenator, is lower than arterial PCO2.
Of note, recirculation was obvious when hemodialysis
catheters were used, even with the lowest blood flow
Figure 2 Partial pressure of arterial carbon dioxide (PaCO2) depending on blood flow. A) 14.5Fr catheter; 8 L/minute sweep gas flow. B)
14.5Fr catheter; 16 L/minute sweep gas flow. C) 19Fr catheter; 8 L/minute sweep gas flow. D) 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.
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genator than in the arterial blood (Figure 6A and B). In
contrast, the specifically designed 19Fr catheter pro-
duced no significant recirculation, represented by higher
CO2 before oxygenator than in arterial blood (Figure 6C
and D). Therefore, (1) blood flow rates and (2) the specific
technical design of the catheter that prevents recirculation
are the main determinants of successful ECCO2R. Fur-
thermore, CO2 elimination of the oxygenator depends
closely on the diffusion gradient of CO2 between venous
blood and the sweep gas. Therefore, with a higher CO2
content in venous blood, more CO2 will be eliminated,
which has to be taken into consideration at the beginning
of the experiments, when PvCO2 is highest. Furthermore,
PaCO2 and PvCO2 were slightly higher in the low-flow
group with the 19Fr than with the 14.5Fr catheter.
In the 1970’s, Kolobow [26] and Gattinoni [27] indi-
cated that ECCO2R is dependent not only on venous
PCO2, blood flow and sweep gas flow, but also on the
size of the oxygenator. The currently used oxygenator
provides a surface area of 0.98 m2 without heat exchange
fibers. The high efficiency of the system is reflected by a
very low mean PaCO2 value, leading to alkalotic pH
values in the blood that is delivered by the oxygenator atlow blood flow rates. This may explain why the previ-
ously described linear relationship between sweep gas
flow and ECCO2R was not observed [22,24,28]. As
shown by the present study, sweep gas flow rates of
more than 6 L/minute, but not lower flow rates, can
sufficiently maintain an optimal ECCO2R when a blood
flow rate of 1,000 ml/minute is applied.
Interestingly, ECCO2R tended to be more efficient
when 100% oxygen was switched to room air sweep gas.
As hypercapnic respiratory failure is not necessarily as-
sociated with severe hypoxemia, the use of air as a sweep
gas may slightly improve the effectiveness of ECCO2R,
but will also reduce the oxygen transfer capacity of the
extracorporeal support. On the other hand, the applica-
tion of oxygen sweep gas was sufficient to improve oxy-
genation when the ratio of catheter blood flow rate to
cardiac output was relatively high, in line with previous
results [24].
The current study has some limitations. First, data ac-
quired in animals cannot automatically be transferred
into a clinical setting; however, the animals showed CO2
production and cardiac output rates that were similar to
those observed in adult humans. Previous studies in
humans have already shown the clinical effects of ECCO2R;
Figure 3 pH dependence on blood flow. A) 14.5Fr catheter; 8 L/minute sweep gas flow. B) 14.5Fr catheter; 16 L/minute sweep gas flow. C)
19Fr catheter; 8 L/minute sweep gas flow. D) 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.
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standing the physiology of ECCO2R in humans as well.
Furthermore, the anatomy of the pig is not comparable to
a human adult, and the catheters we used may not be ideal
in clinical practice. However, the perfect cannula for CO2
removal still has to be designed. Second, the typical clinical
scenario of exacerbated COPD with severe airflow limita-
tion was not simulated, since a rather high dead space ven-
tilation protocol was used to artificially increase PaCO2.
Therefore, the interaction between ECCO2R and mechan-
ical ventilation could not be investigated. This, however, is
suggested to be of clinical importance, since severe airflow










0 0 91.3 ± 11.6 7.16 ± 0.07 137.1 ± 26.8
200 62.4 ± 12.2 85.6 ± 12.0 7.20 ± 0.06 167.6 ± 27.4
400 77.9 ± 17.4 82.3 ± 15.0 7.22 ± 0.07 173.3 ± 21.6
Fr, French; PaCO2, partial pressure of CO2 in arterial blood; PaO2, partial
pressure of O2 in the arterial blood.settings. This, in turn, can lead to reduced alveolar ventila-
tion that potentially impacts on acidosis. Third, the present
study only applied short-term ECCO2R. In a real-life set-
ting, the long-term effects of blood flow, cannula size and
sweep gas flow application need to be elucidated, since CO2
is also stored in the form of HCO3 in slow compartments,
and it may take several hours until a steady-state is
reached. This is particularly pertinent to patients with
acute-on-chronic ventilatory failure who present with
respiratory acidosis, hypercapnia and high bicarbonate
levels. On the other hand, the time constant for redu-










0 0 107.9 ± 20.7 7.13 ± 0.08 122.9 ± 29.4
250 83.4 ± 11.8 90.3 ± 13.5 7.20 ± 0.06 142.8 ± 35.8
500 118.7 ± 23.9 76.9 ± 9.6 7.27 ± 0.06 165.3 ± 39.8
750 138.3 ± 22.8 66.9 ± 11.1 7.34 ± 0.09 182.0 ± 42.6
1,000 146.1 ± 22.6 55.7 ± 10.5 7.41 ± 0.07 193.6 ± 41.0
Figure 4 Normalized elimination of carbon dioxide (CO2) depending on blood flow. A) 14.5Fr catheter; 8 L/minute sweep gas flow. B)
14.5Fr catheter; 16 L/minute sweep gas flow. C) 19Fr catheter; 8 L/minute sweep gas flow. D) 19Fr catheter; 16 L/minute sweep gas flow.
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been an adequate amount of time to detect any changes
in PaCO2. Furthermore, in the present study we did not
put the focus on anticoagulation since clotting was no
issue in our short-term experiments of 12 hours duration.Figure 5 Elimination of carbon dioxide (CO2) in dependence of
sweep gas flow under a fixed flood flow of 1,000 ml/minute
using a 19Fr catheter. Fr, French.Further studies have to be done in humans, since low-flow
devices may need more anticoagulation in comparison
to high-flow extracorporeal membrane oxygenation
(ECMO). Finally, only one system for ECCO2R was tested
in the present study, and this is suggested to limit the
comparison of the current trial with other trials, in which
different systems have been used. Nevertheless, the cur-
rently used system has shown to be highly effective for
ECCO2R represented by a PCO2 lower than 10 mmHg
and a PO2 of 600 mmHg after the oxygenator with low
blood flows. Although other systems function in a differ-
ent way, it is physically difficult to further lower PCO2.
Thus, we believe that the present study is valid to system-
atically show changes in physiology during ECCO2R when
using different conditions.
Conclusions
In conclusion, this animal study has shown that severe
respiratory acidosis can be successfully managed by veno-
venous ECCO2R, but only when blood flow rates ranging
between 750 and 1,000 ml/minute are applied. For this
purpose, the use of specifically-designed catheters with
an inner diameter greater than that of the typical
hemodialysis catheters are required to establish flow
rates ranging between 750 and 1,000 ml/minute and to
Figure 6 Partial pressure of arterial (PaCO2) and venous (PvCO2) carbon dioxide depending on blood flow, sweep gas flow and
cannula size. A) 14.5Fr catheter; 8 L/minute sweep gas flow. B) 14.5Fr catheter; 16 L/minute sweep gas flow. C) 19Fr catheter; 8 L/minute sweep
gas flow. D) 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.
Karagiannidis et al. Critical Care 2014, 18:R124 Page 8 of 10
http://ccforum.com/content/18/3/R124avoid blood recirculation. In addition, the study has
shown that a sweep gas flow rate above 6 L/minute is
of minor importance for ECCO2R when using modern,
highly-efficient oxygenators with low blood-flow rates.
This holds true for the system tested, which is highly
effective, represented by a PvCO2 of 10 to 30 mmHg
after the oxygenator and, therefore, may be translated
to comparable systems. This study also suggests that
low-flow veno-venous ECCO2R with modern miniaturized
membrane lungs can serve as a treatment option for severe
respiratory acidosis associated with acute respiratory failure
and severe hypercapnia. Whether these techniques prove
to be suitable to avoid endotracheal intubation or to facili-
tate early extubation in intubated patients needs to be elu-
cidated by future clinical trials.
Key messages
 Severe respiratory acidosis with pH values of 7.0 to
7.2 can be successfully managed by veno-venous
ECCO2R. For this purpose, blood flow rates ranging between
750 and 1,000 ml/minute are mandatory.
 Specifically-designed catheters aimed at avoiding
blood recirculation warranting the target blood flow
are required.
 Sweep gas flow rates above 6 L/minute are sufficient
for maximal ECCO2R.
Additional file
Additional file 1: Absolute values of CO2 elimination and blood gas
analysis with a sweep gas flow of 8 L O2/minute depending on
blood flow. The table shows the CO2 elimination capacity of the ECCO2R
system and the corresponding blood gas analysis with a sweep gas flow
of 8 L O2/minute with a hemodialysis catheter (A) and the 19Fr Bicaval
Dual Lumen Catheter (B) according to different blood flow levels. It is
clearly shown that ECCO2R is less efficient with the 14.5Fr catheter (A)
compared to the 19Fr Bicaval Dual Lumen Catheter (B).
Abbreviation
ARDS: acute respiratory distress syndrome; COPD: chronic obstructive
pulmonary disease; ECCO2R: extracorporeal CO2 removal;
ECMO: extracorporeal membrane oxygenation; Fr: French; PaCO2: partial
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PCO2: partial pressure of CO2; PEEP: positive end expiratory pressure;
PVCO2: partial pressure of CO2 in venous blood; NIV: non-invasive ventilation.
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